Prostate Cancer

My wife and children were by my side as I underwent grueling and life-changing prostate cancer treatment.

When compared with Zytiga, Xtandi appeared to have a lower incidence of infection among men with prostate cancer, especially those under 70 years.

Nubeqa plus androgen deprivation therapy displayed positive radiological progression-free survival results in early trial data.

Patients with favorable-risk prostate cancer “should be aware that they don't need treatment right away,” one expert said.

During my "watch and wait" time for prostate cancer, I spend this time wisely on things like attending writing webinars.

Leaning on spiritual belief may strengthen patients' life purposes, but for many, it's common to temporarily loosen their grip on faith after a cancer diagnosis.

As part of the “Speaking Out” series, a radiation oncologist discusses the benefits of MRI-guided stereotactic body radiation therapy.

From the NBA’s Alonzo Mourning opening up about his prostate surgery to an actor from “Felicity” dying of cancer, here’s what is happening in the oncology space this week.

Two years of postsurgical androgen deprivation therapy resulted in a 10-year metastasis-free survival rate of nearly 80%.

Treatment with Pluvicto following ARPI resulted in favorable progression and response outcomes in PSMA-positive mCRPR.

From Michael Richards revealing his prostate cancer diagnosis to MLB Hall-of-Famer Ryne Sandberg being cancer-free, here’s what’s happening in the oncology space this week.

Whole-pelvic radiation conferred a 67% lower risk of all-cause mortality among patients younger than 65 with unfavorable-risk prostate cancer.

Stereotactic body radiotherapy and hormone treatment resulted in 40.1% 12-month progression-free survival in a recent study.

From Olivia Munn opening up about undergoing a hysterectomy and egg retrieval to Michael McDonald’s learned lesson after his wife’s cancer, here’s what’s going on in the oncology space this week.

The postsurgical combination of androgen deprivation therapy and Erleada has shown promising results in prostate cancer.

When I found out my PSA levels were rising, I was so overwhelmed moments leading up to my telehealth session with my urologist.

Treatment with a certain radiation therapy worsens quality of life in patients with prostate cancer. An expert explains ways to mitigate side effects.

From the Allman Brothers Band’s singer Dickey Betts dying after a cancer diagnosis to the “Shopaholic” author announcing her glioblastoma diagnosis, here’s what is happening in the cancer space this week.

Topline data has been released from a trial of antibody-drug conjugate FG-3246 for patients with pretreated, metastatic castration-resistant prostate cancer.

Compared to other treatments, patients’ testosterone levels return to baseline levels faster following treatment with Orgovyx.

Patients with prostate cancer receiving ADT who are vitamin D deficient may receive the most bone density benefits from high-dose vitamin D.

When experiencing loss, always look forward and have hope.

My prostate cancer has come back and stronger, but so have I.

Researchers on a phase 1/2 trial provided the first dose of gotistobart plus Pluvicto to a specific patient population with prostate cancer.

A UCLA neurobiology professor and prostate cancer survivor discuss using artificial intelligence to map his disease and inform treatment decisions.

Prostate cancer survivors who had a more plant-based diet tended to have fewer sexual and urinary side effects, research showed.

The Food and Drug Administration has granted a Fast Track designation to the novel immune activator drug BXCL701 in combination with a checkpoint inhibitor for patients with metastatic small cell neuroendocrine prostate cancer (SCNC).

Patients with high-risk prostate cancer who had a higher dose of radiation plus long-term androgen deprivation therapy tended to live longer than those who had a lower dose.

Fear overtook my mind as I received rounds of scans for prostate cancer when my PSA results surged.

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.